Evaluation of Lymphatic Filariasis and Onchocerciasis in Three Senegalese Districts Treated for Onchocerciasis with Ivermectin.
Identifieur interne : 001099 ( Main/Exploration ); précédent : 001098; suivant : 001100Evaluation of Lymphatic Filariasis and Onchocerciasis in Three Senegalese Districts Treated for Onchocerciasis with Ivermectin.
Auteurs : Nana O. Wilson [États-Unis] ; Alioune Badara Ly [Sénégal] ; Vitaliano A. Cama [États-Unis] ; Paul T. Cantey [États-Unis] ; Daniel Cohn [États-Unis] ; Lamine Diawara [Sénégal] ; Abdel Direny [Haïti] ; Mawo Fall [Sénégal] ; Karla R. Feeser [États-Unis] ; Leanne M. Fox [États-Unis] ; Achille Kabore [États-Unis] ; Amadou F. Seck [Sénégal] ; Ngayo Sy [Sénégal] ; Daouda Ndiaye [Sénégal] ; Christine Dubray [États-Unis]Source :
- PLoS neglected tropical diseases [ 1935-2735 ] ; 2016.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Anticorps antihelminthe (sang), Enfant, Enfant d'âge préscolaire, Femelle, Filariose lymphatique (sang), Filariose lymphatique (traitement médicamenteux), Filariose lymphatique (épidémiologie), Humains, Ivermectine (usage thérapeutique), Jeune adulte, Mâle, Onchocercose (sang), Onchocercose (traitement médicamenteux), Onchocercose (épidémiologie), Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Sénégal (épidémiologie).
- MESH :
- sang : Anticorps antihelminthe, Filariose lymphatique, Onchocercose.
- traitement médicamenteux : Filariose lymphatique, Onchocercose.
- usage thérapeutique : Ivermectine.
- épidémiologie : Filariose lymphatique, Onchocercose, Sénégal.
- Adolescent, Adulte, Adulte d'âge moyen, Enfant, Enfant d'âge préscolaire, Femelle, Humains, Jeune adulte, Mâle, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Helminth (blood), Child, Child, Preschool, Elephantiasis, Filarial (blood), Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (epidemiology), Female, Humans, Ivermectin (therapeutic use), Male, Middle Aged, Onchocerciasis (blood), Onchocerciasis (drug therapy), Onchocerciasis (epidemiology), Senegal (epidemiology), Treatment Outcome, Young Adult.
- MESH :
- chemical , blood : Antibodies, Helminth.
- blood : Elephantiasis, Filarial, Onchocerciasis.
- drug therapy : Elephantiasis, Filarial, Onchocerciasis.
- epidemiology : Elephantiasis, Filarial, Onchocerciasis, Senegal.
- chemical , therapeutic use : Ivermectin.
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Humans, Male, Middle Aged, Treatment Outcome, Young Adult.
Abstract
In Africa, onchocerciasis and lymphatic filariasis (LF) are co-endemic in many areas. Current efforts to eliminate both diseases are through ivermectin-based mass drug administration (MDA). Years of ivermectin distribution for onchocerciasis may have interrupted LF transmission in certain areas. The Kédougou region, Senegal, is co-endemic for LF and onchocerciasis. Though MDA for onchocerciasis started in 1988, in 2014 albendazole had not yet been added for LF. The objective of this study was to assess in an integrated manner the LF and onchocerciasis status in the three districts of the Kédougou region after ≥10 years of ivermectin-based MDA. The study employed an African Programme for Onchocerciasis Control (APOC) onchocerciasis-related methodology. In the three districts, 14 villages close to three rivers that have Simulium damnosum breeding sites were surveyed. Convenience sampling of residents ≥5 years old was performed. Assessment for LF antigenemia by immunochromatographic testing (ICT) was added to skin snip microscopy for onchocerciasis. Participants were also tested for antibodies against Wb123 (LF) and Ov16 (onchocerciasis) antigens. In two districts, no participants were ICT or skin snip positive. In the third district, 3.5% were ICT positive and 0.7% were skin snip positive. In all the three districts, Wb123 prevalence was 0.6%. Overall, Ov16 prevalence was 6.9%. Ov16 prevalence among children 5-9 years old in the study was 2.5%. LF antigenemia prevalence was still above treatment threshold in one district despite ≥10 years of ivermectin-based MDA. The presence of Ov16 positive children suggested recent transmission of Onchocerca volvulus. This study showed the feasibility of integrated evaluation of onchocerciasis and LF but development of integrated robust methods for assessing transmission of both LF and onchocerciasis are needed to determine where MDA can be stopped safely in co-endemic areas.
DOI: 10.1371/journal.pntd.0005198
PubMed: 27926918
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000480
- to stream PubMed, to step Curation: 000480
- to stream PubMed, to step Checkpoint: 000480
- to stream Ncbi, to step Merge: 008A84
- to stream Ncbi, to step Curation: 008A84
- to stream Ncbi, to step Checkpoint: 008A84
- to stream Main, to step Merge: 001101
- to stream Main, to step Curation: 001099
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluation of Lymphatic Filariasis and Onchocerciasis in Three Senegalese Districts Treated for Onchocerciasis with Ivermectin.</title><author><name sortKey="Wilson, Nana O" sort="Wilson, Nana O" uniqKey="Wilson N" first="Nana O" last="Wilson">Nana O. Wilson</name><affiliation wicri:level="2"><nlm:affiliation>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Badara Ly, Alioune" sort="Badara Ly, Alioune" uniqKey="Badara Ly A" first="Alioune" last="Badara Ly">Alioune Badara Ly</name><affiliation wicri:level="1"><nlm:affiliation>Ministère de la Santé et de l'Action Sociale, Dakar, Senegal.</nlm:affiliation><country xml:lang="fr">Sénégal</country><wicri:regionArea>Ministère de la Santé et de l'Action Sociale, Dakar</wicri:regionArea><wicri:noRegion>Dakar</wicri:noRegion></affiliation></author><author><name sortKey="Cama, Vitaliano A" sort="Cama, Vitaliano A" uniqKey="Cama V" first="Vitaliano A" last="Cama">Vitaliano A. Cama</name><affiliation wicri:level="2"><nlm:affiliation>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Cantey, Paul T" sort="Cantey, Paul T" uniqKey="Cantey P" first="Paul T" last="Cantey">Paul T. Cantey</name><affiliation wicri:level="2"><nlm:affiliation>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Cohn, Daniel" sort="Cohn, Daniel" uniqKey="Cohn D" first="Daniel" last="Cohn">Daniel Cohn</name><affiliation wicri:level="2"><nlm:affiliation>RTI International, Washington, DC, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>RTI International, Washington, DC</wicri:regionArea><placeName><region type="state">District de Columbia</region></placeName></affiliation></author><author><name sortKey="Diawara, Lamine" sort="Diawara, Lamine" uniqKey="Diawara L" first="Lamine" last="Diawara">Lamine Diawara</name><affiliation wicri:level="1"><nlm:affiliation>World Health Organization, Regional Office for Africa, Senegal.</nlm:affiliation><country xml:lang="fr">Sénégal</country><wicri:regionArea>World Health Organization, Regional Office for Africa</wicri:regionArea><wicri:noRegion>Regional Office for Africa</wicri:noRegion></affiliation></author><author><name sortKey="Direny, Abdel" sort="Direny, Abdel" uniqKey="Direny A" first="Abdel" last="Direny">Abdel Direny</name><affiliation wicri:level="1"><nlm:affiliation>IMA World Health, Port-au-Prince, Haiti.</nlm:affiliation><country xml:lang="fr">Haïti</country><wicri:regionArea>IMA World Health, Port-au-Prince</wicri:regionArea><wicri:noRegion>Port-au-Prince</wicri:noRegion></affiliation></author><author><name sortKey="Fall, Mawo" sort="Fall, Mawo" uniqKey="Fall M" first="Mawo" last="Fall">Mawo Fall</name><affiliation wicri:level="1"><nlm:affiliation>RTI/ENVISION, Dakar, Senegal.</nlm:affiliation><country xml:lang="fr">Sénégal</country><wicri:regionArea>RTI/ENVISION, Dakar</wicri:regionArea><wicri:noRegion>Dakar</wicri:noRegion></affiliation></author><author><name sortKey="Feeser, Karla R" sort="Feeser, Karla R" uniqKey="Feeser K" first="Karla R" last="Feeser">Karla R. Feeser</name><affiliation wicri:level="2"><nlm:affiliation>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Fox, Leanne M" sort="Fox, Leanne M" uniqKey="Fox L" first="Leanne M" last="Fox">Leanne M. Fox</name><affiliation wicri:level="2"><nlm:affiliation>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Kabore, Achille" sort="Kabore, Achille" uniqKey="Kabore A" first="Achille" last="Kabore">Achille Kabore</name><affiliation wicri:level="2"><nlm:affiliation>RTI International, Washington, DC, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>RTI International, Washington, DC</wicri:regionArea><placeName><region type="state">District de Columbia</region></placeName></affiliation></author><author><name sortKey="Seck, Amadou F" sort="Seck, Amadou F" uniqKey="Seck A" first="Amadou F" last="Seck">Amadou F. Seck</name><affiliation wicri:level="1"><nlm:affiliation>Ministère de la Santé et de l'Action Sociale, Dakar, Senegal.</nlm:affiliation><country xml:lang="fr">Sénégal</country><wicri:regionArea>Ministère de la Santé et de l'Action Sociale, Dakar</wicri:regionArea><wicri:noRegion>Dakar</wicri:noRegion></affiliation></author><author><name sortKey="Sy, Ngayo" sort="Sy, Ngayo" uniqKey="Sy N" first="Ngayo" last="Sy">Ngayo Sy</name><affiliation wicri:level="1"><nlm:affiliation>Service de Lutte Antiparasitaire, Ministère de la Santé et de l'Action Sociale, Thies, Senegal.</nlm:affiliation><country xml:lang="fr">Sénégal</country><wicri:regionArea>Service de Lutte Antiparasitaire, Ministère de la Santé et de l'Action Sociale, Thies</wicri:regionArea><wicri:noRegion>Thies</wicri:noRegion></affiliation></author><author><name sortKey="Ndiaye, Daouda" sort="Ndiaye, Daouda" uniqKey="Ndiaye D" first="Daouda" last="Ndiaye">Daouda Ndiaye</name><affiliation wicri:level="1"><nlm:affiliation>University Cheikh Anta Diop, Dakar, Senegal.</nlm:affiliation><country xml:lang="fr">Sénégal</country><wicri:regionArea>University Cheikh Anta Diop, Dakar</wicri:regionArea><wicri:noRegion>Dakar</wicri:noRegion></affiliation></author><author><name sortKey="Dubray, Christine" sort="Dubray, Christine" uniqKey="Dubray C" first="Christine" last="Dubray">Christine Dubray</name><affiliation wicri:level="2"><nlm:affiliation>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27926918</idno><idno type="pmid">27926918</idno><idno type="doi">10.1371/journal.pntd.0005198</idno><idno type="wicri:Area/PubMed/Corpus">000480</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000480</idno><idno type="wicri:Area/PubMed/Curation">000480</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000480</idno><idno type="wicri:Area/PubMed/Checkpoint">000480</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000480</idno><idno type="wicri:Area/Ncbi/Merge">008A84</idno><idno type="wicri:Area/Ncbi/Curation">008A84</idno><idno type="wicri:Area/Ncbi/Checkpoint">008A84</idno><idno type="wicri:Area/Main/Merge">001101</idno><idno type="wicri:Area/Main/Curation">001099</idno><idno type="wicri:Area/Main/Exploration">001099</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Evaluation of Lymphatic Filariasis and Onchocerciasis in Three Senegalese Districts Treated for Onchocerciasis with Ivermectin.</title><author><name sortKey="Wilson, Nana O" sort="Wilson, Nana O" uniqKey="Wilson N" first="Nana O" last="Wilson">Nana O. Wilson</name><affiliation wicri:level="2"><nlm:affiliation>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Badara Ly, Alioune" sort="Badara Ly, Alioune" uniqKey="Badara Ly A" first="Alioune" last="Badara Ly">Alioune Badara Ly</name><affiliation wicri:level="1"><nlm:affiliation>Ministère de la Santé et de l'Action Sociale, Dakar, Senegal.</nlm:affiliation><country xml:lang="fr">Sénégal</country><wicri:regionArea>Ministère de la Santé et de l'Action Sociale, Dakar</wicri:regionArea><wicri:noRegion>Dakar</wicri:noRegion></affiliation></author><author><name sortKey="Cama, Vitaliano A" sort="Cama, Vitaliano A" uniqKey="Cama V" first="Vitaliano A" last="Cama">Vitaliano A. Cama</name><affiliation wicri:level="2"><nlm:affiliation>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Cantey, Paul T" sort="Cantey, Paul T" uniqKey="Cantey P" first="Paul T" last="Cantey">Paul T. Cantey</name><affiliation wicri:level="2"><nlm:affiliation>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Cohn, Daniel" sort="Cohn, Daniel" uniqKey="Cohn D" first="Daniel" last="Cohn">Daniel Cohn</name><affiliation wicri:level="2"><nlm:affiliation>RTI International, Washington, DC, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>RTI International, Washington, DC</wicri:regionArea><placeName><region type="state">District de Columbia</region></placeName></affiliation></author><author><name sortKey="Diawara, Lamine" sort="Diawara, Lamine" uniqKey="Diawara L" first="Lamine" last="Diawara">Lamine Diawara</name><affiliation wicri:level="1"><nlm:affiliation>World Health Organization, Regional Office for Africa, Senegal.</nlm:affiliation><country xml:lang="fr">Sénégal</country><wicri:regionArea>World Health Organization, Regional Office for Africa</wicri:regionArea><wicri:noRegion>Regional Office for Africa</wicri:noRegion></affiliation></author><author><name sortKey="Direny, Abdel" sort="Direny, Abdel" uniqKey="Direny A" first="Abdel" last="Direny">Abdel Direny</name><affiliation wicri:level="1"><nlm:affiliation>IMA World Health, Port-au-Prince, Haiti.</nlm:affiliation><country xml:lang="fr">Haïti</country><wicri:regionArea>IMA World Health, Port-au-Prince</wicri:regionArea><wicri:noRegion>Port-au-Prince</wicri:noRegion></affiliation></author><author><name sortKey="Fall, Mawo" sort="Fall, Mawo" uniqKey="Fall M" first="Mawo" last="Fall">Mawo Fall</name><affiliation wicri:level="1"><nlm:affiliation>RTI/ENVISION, Dakar, Senegal.</nlm:affiliation><country xml:lang="fr">Sénégal</country><wicri:regionArea>RTI/ENVISION, Dakar</wicri:regionArea><wicri:noRegion>Dakar</wicri:noRegion></affiliation></author><author><name sortKey="Feeser, Karla R" sort="Feeser, Karla R" uniqKey="Feeser K" first="Karla R" last="Feeser">Karla R. Feeser</name><affiliation wicri:level="2"><nlm:affiliation>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Fox, Leanne M" sort="Fox, Leanne M" uniqKey="Fox L" first="Leanne M" last="Fox">Leanne M. Fox</name><affiliation wicri:level="2"><nlm:affiliation>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Kabore, Achille" sort="Kabore, Achille" uniqKey="Kabore A" first="Achille" last="Kabore">Achille Kabore</name><affiliation wicri:level="2"><nlm:affiliation>RTI International, Washington, DC, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>RTI International, Washington, DC</wicri:regionArea><placeName><region type="state">District de Columbia</region></placeName></affiliation></author><author><name sortKey="Seck, Amadou F" sort="Seck, Amadou F" uniqKey="Seck A" first="Amadou F" last="Seck">Amadou F. Seck</name><affiliation wicri:level="1"><nlm:affiliation>Ministère de la Santé et de l'Action Sociale, Dakar, Senegal.</nlm:affiliation><country xml:lang="fr">Sénégal</country><wicri:regionArea>Ministère de la Santé et de l'Action Sociale, Dakar</wicri:regionArea><wicri:noRegion>Dakar</wicri:noRegion></affiliation></author><author><name sortKey="Sy, Ngayo" sort="Sy, Ngayo" uniqKey="Sy N" first="Ngayo" last="Sy">Ngayo Sy</name><affiliation wicri:level="1"><nlm:affiliation>Service de Lutte Antiparasitaire, Ministère de la Santé et de l'Action Sociale, Thies, Senegal.</nlm:affiliation><country xml:lang="fr">Sénégal</country><wicri:regionArea>Service de Lutte Antiparasitaire, Ministère de la Santé et de l'Action Sociale, Thies</wicri:regionArea><wicri:noRegion>Thies</wicri:noRegion></affiliation></author><author><name sortKey="Ndiaye, Daouda" sort="Ndiaye, Daouda" uniqKey="Ndiaye D" first="Daouda" last="Ndiaye">Daouda Ndiaye</name><affiliation wicri:level="1"><nlm:affiliation>University Cheikh Anta Diop, Dakar, Senegal.</nlm:affiliation><country xml:lang="fr">Sénégal</country><wicri:regionArea>University Cheikh Anta Diop, Dakar</wicri:regionArea><wicri:noRegion>Dakar</wicri:noRegion></affiliation></author><author><name sortKey="Dubray, Christine" sort="Dubray, Christine" uniqKey="Dubray C" first="Christine" last="Dubray">Christine Dubray</name><affiliation wicri:level="2"><nlm:affiliation>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author></analytic><series><title level="j">PLoS neglected tropical diseases</title><idno type="eISSN">1935-2735</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antibodies, Helminth (blood)</term><term>Child</term><term>Child, Preschool</term><term>Elephantiasis, Filarial (blood)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (epidemiology)</term><term>Female</term><term>Humans</term><term>Ivermectin (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Onchocerciasis (blood)</term><term>Onchocerciasis (drug therapy)</term><term>Onchocerciasis (epidemiology)</term><term>Senegal (epidemiology)</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps antihelminthe (sang)</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Filariose lymphatique (sang)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Filariose lymphatique (épidémiologie)</term><term>Humains</term><term>Ivermectine (usage thérapeutique)</term><term>Jeune adulte</term><term>Mâle</term><term>Onchocercose (sang)</term><term>Onchocercose (traitement médicamenteux)</term><term>Onchocercose (épidémiologie)</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Sénégal (épidémiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Helminth</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Onchocerciasis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Onchocerciasis</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Onchocerciasis</term><term>Senegal</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antihelminthe</term><term>Filariose lymphatique</term><term>Onchocercose</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term><term>Onchocercose</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Filariose lymphatique</term><term>Onchocercose</term><term>Sénégal</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In Africa, onchocerciasis and lymphatic filariasis (LF) are co-endemic in many areas. Current efforts to eliminate both diseases are through ivermectin-based mass drug administration (MDA). Years of ivermectin distribution for onchocerciasis may have interrupted LF transmission in certain areas. The Kédougou region, Senegal, is co-endemic for LF and onchocerciasis. Though MDA for onchocerciasis started in 1988, in 2014 albendazole had not yet been added for LF. The objective of this study was to assess in an integrated manner the LF and onchocerciasis status in the three districts of the Kédougou region after ≥10 years of ivermectin-based MDA. The study employed an African Programme for Onchocerciasis Control (APOC) onchocerciasis-related methodology. In the three districts, 14 villages close to three rivers that have Simulium damnosum breeding sites were surveyed. Convenience sampling of residents ≥5 years old was performed. Assessment for LF antigenemia by immunochromatographic testing (ICT) was added to skin snip microscopy for onchocerciasis. Participants were also tested for antibodies against Wb123 (LF) and Ov16 (onchocerciasis) antigens. In two districts, no participants were ICT or skin snip positive. In the third district, 3.5% were ICT positive and 0.7% were skin snip positive. In all the three districts, Wb123 prevalence was 0.6%. Overall, Ov16 prevalence was 6.9%. Ov16 prevalence among children 5-9 years old in the study was 2.5%. LF antigenemia prevalence was still above treatment threshold in one district despite ≥10 years of ivermectin-based MDA. The presence of Ov16 positive children suggested recent transmission of Onchocerca volvulus. This study showed the feasibility of integrated evaluation of onchocerciasis and LF but development of integrated robust methods for assessing transmission of both LF and onchocerciasis are needed to determine where MDA can be stopped safely in co-endemic areas.</div></front></TEI><affiliations><list><country><li>Haïti</li><li>Sénégal</li><li>États-Unis</li></country><region><li>District de Columbia</li><li>Géorgie (États-Unis)</li></region></list><tree><country name="États-Unis"><region name="Géorgie (États-Unis)"><name sortKey="Wilson, Nana O" sort="Wilson, Nana O" uniqKey="Wilson N" first="Nana O" last="Wilson">Nana O. Wilson</name></region><name sortKey="Cama, Vitaliano A" sort="Cama, Vitaliano A" uniqKey="Cama V" first="Vitaliano A" last="Cama">Vitaliano A. Cama</name><name sortKey="Cantey, Paul T" sort="Cantey, Paul T" uniqKey="Cantey P" first="Paul T" last="Cantey">Paul T. Cantey</name><name sortKey="Cohn, Daniel" sort="Cohn, Daniel" uniqKey="Cohn D" first="Daniel" last="Cohn">Daniel Cohn</name><name sortKey="Dubray, Christine" sort="Dubray, Christine" uniqKey="Dubray C" first="Christine" last="Dubray">Christine Dubray</name><name sortKey="Feeser, Karla R" sort="Feeser, Karla R" uniqKey="Feeser K" first="Karla R" last="Feeser">Karla R. Feeser</name><name sortKey="Fox, Leanne M" sort="Fox, Leanne M" uniqKey="Fox L" first="Leanne M" last="Fox">Leanne M. Fox</name><name sortKey="Kabore, Achille" sort="Kabore, Achille" uniqKey="Kabore A" first="Achille" last="Kabore">Achille Kabore</name></country><country name="Sénégal"><noRegion><name sortKey="Badara Ly, Alioune" sort="Badara Ly, Alioune" uniqKey="Badara Ly A" first="Alioune" last="Badara Ly">Alioune Badara Ly</name></noRegion><name sortKey="Diawara, Lamine" sort="Diawara, Lamine" uniqKey="Diawara L" first="Lamine" last="Diawara">Lamine Diawara</name><name sortKey="Fall, Mawo" sort="Fall, Mawo" uniqKey="Fall M" first="Mawo" last="Fall">Mawo Fall</name><name sortKey="Ndiaye, Daouda" sort="Ndiaye, Daouda" uniqKey="Ndiaye D" first="Daouda" last="Ndiaye">Daouda Ndiaye</name><name sortKey="Seck, Amadou F" sort="Seck, Amadou F" uniqKey="Seck A" first="Amadou F" last="Seck">Amadou F. Seck</name><name sortKey="Sy, Ngayo" sort="Sy, Ngayo" uniqKey="Sy N" first="Ngayo" last="Sy">Ngayo Sy</name></country><country name="Haïti"><noRegion><name sortKey="Direny, Abdel" sort="Direny, Abdel" uniqKey="Direny A" first="Abdel" last="Direny">Abdel Direny</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001099 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001099 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27926918
|texte= Evaluation of Lymphatic Filariasis and Onchocerciasis in Three Senegalese Districts Treated for Onchocerciasis with Ivermectin.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27926918" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |